MVA Expressing Modified HIV Envelope, Gag, and Pol Gene

PROBLEM TO BE SOLVED: To control pathogenic immunodeficiency virus. ; SOLUTION: There is provided a pharmaceutical composition comprising a recombinant MVA virus expressing an HIV env, gag, and pol gene or modified gene thereof for production of an HIV Env, Gag, and Pol antigen by expression from the virus, and a pharmaceutically acceptable carrier, wherein the HIV env gene is modified to encode an HIV Env protein which is composed of gp120 and the membrane-spanning domain and ectodomain of gp41 but lacking a part or all of the cytoplasmic domain of gp41. ; COPYRIGHT: (C)2010,JPO&INPIT

Patents:
JP 2,010,115,208   [MORE INFO]

Inventor(s): MOSS BERNARD; WYATT LINDA; EARL PATRICIA; ROBINSON HARRIET L

Type of Offer: Licensing



« More Pharmaceutical Patents

---